Literature DB >> 11018453

The third-stage larva (L3) of Brugia: its role in immune modulation and protective immunity.

E Devaney1, J Osborne.   

Abstract

In this review, we focus on the role of the L3 (third-stage larva) of lymphatic filarial nematodes in immunomodulation and in the development of protective immunity. Studies in the mouse models of Brugia have been fundamental to our understanding of the mechanisms by which infection with L3 results in Th2 responses and the active suppression of Th1 responses. The relevance of these phenomena to the human infection is discussed.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11018453     DOI: 10.1016/s1286-4579(00)01290-9

Source DB:  PubMed          Journal:  Microbes Infect        ISSN: 1286-4579            Impact factor:   2.700


  15 in total

1.  NK T cells are a source of early interleukin-4 following infection with third-stage larvae of the filarial nematode Brugia pahangi.

Authors:  Paul Balmer; Eileen Devaney
Journal:  Infect Immun       Date:  2002-04       Impact factor: 3.441

2.  In vivo exposure of murine dendritic cell and macrophage bone marrow progenitors to the phosphorylcholine-containing filarial nematode glycoprotein ES-62 polarizes their differentiation to an anti-inflammatory phenotype.

Authors:  Helen S Goodridge; Fraser A Marshall; Emma H Wilson; Katrina M Houston; Foo Y Liew; Margaret M Harnett; William Harnett
Journal:  Immunology       Date:  2004-12       Impact factor: 7.397

3.  Effects of gamma radiation on Brugia malayi infective larvae and their intracellular Wolbachia bacteria.

Authors:  R Rao; H Moussa; R P Vanderwaal; E Sampson; L J Atkinson; G J Weil
Journal:  Parasitol Res       Date:  2005-07-05       Impact factor: 2.289

4.  Leishmania donovani molecules recognized by sera of filaria infected host facilitate filarial infection.

Authors:  Richa Verma; Vikas Kushwaha; Smriti Pandey; Jagadeshwar Reddy Thota; Preeti Vishwakarma; Naveen Parmar; Pawan Kumar Yadav; Prachi Tewari; Susanta Kar; Praveen Kumar Shukla; Puvvada Kalpana Murthy
Journal:  Parasitol Res       Date:  2018-06-26       Impact factor: 2.289

5.  Infection outcome and cytokine gene expression in Brugia pahangi- infected gerbils (Meriones unguiculatus) sensitized with Brucella abortus.

Authors:  Sharon R Chirgwin; Philip H Elzer; Sharon U Coleman; Jena M Nowling; Sue D Hagius; Matthew D Edmonds; Thomas R Klei
Journal:  Infect Immun       Date:  2002-11       Impact factor: 3.441

6.  Differential cytokine and antibody responses to adult and larval stages of Onchocerca volvulus consistent with the development of concomitant immunity.

Authors:  Angus J MacDonald; Prasad S D Turaga; Carolyn Harmon-Brown; Tracy J Tierney; Kristine E Bennett; Maggie C McCarthy; Scott C Simonek; Peter A Enyong; Daniel W Moukatte; Sara Lustigman
Journal:  Infect Immun       Date:  2002-06       Impact factor: 3.441

7.  Multivalent fusion protein vaccine for lymphatic filariasis.

Authors:  Gajalakshmi Dakshinamoorthy; Abhilash Kumble Samykutty; Gnanasekar Munirathinam; Maryada Venkatarami Reddy; Ramaswamy Kalyanasundaram
Journal:  Vaccine       Date:  2012-10-02       Impact factor: 3.641

8.  The Onchocerca volvulus cysteine proteinase inhibitor, Ov-CPI-2, is a target of protective antibody response that increases with age.

Authors:  Fidelis Cho-Ngwa; Jing Liu; Sara Lustigman
Journal:  PLoS Negl Trop Dis       Date:  2010-08-24

9.  Resistance and susceptibility to filarial infection with Litomosoides sigmodontis are associated with early differences in parasite development and in localized immune reactions.

Authors:  Simon Babayan; Marie-Noëlle Ungeheuer; Coralie Martin; Tarik Attout; Elodie Belnoue; Georges Snounou; Laurent Rénia; Masataka Korenaga; Odile Bain
Journal:  Infect Immun       Date:  2003-12       Impact factor: 3.441

10.  Transcriptomes and pathways associated with infectivity, survival and immunogenicity in Brugia malayi L3.

Authors:  Ben-Wen Li; Amy C Rush; Makedonka Mitreva; Yong Yin; David Spiro; Elodie Ghedin; Gary J Weil
Journal:  BMC Genomics       Date:  2009-06-15       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.